CagriSema (Cagrilintide + Semaglutide)
Also known as Cagrilintide/Semaglutide combination
CagriSema is an investigational combination of cagrilintide, a long-acting amylin analog, and semaglutide, a GLP-1 receptor agonist, co-formulated as a single once-weekly injection. Phase 3 trial data have reported average weight reductions numerically greater than semaglutide alone in some analyses, positioning it among the more effective agents studied for weight management to date. It has not yet received regulatory approval. As with other late-stage investigational agents, published data are still limited relative to long-approved therapies.
Reported benefits
- Associated with greater average weight loss than semaglutide monotherapy in some trial comparisons
- Combines two complementary satiety-signaling pathways
- Once-weekly injection schedule
- May improve glycemic markers
How it works
Cagrilintide activates amylin receptors, which are involved in satiety signaling and slowed gastric emptying, while semaglutide activates GLP-1 receptors with similar downstream appetite and gastric-emptying effects. The combination is intended to engage two complementary satiety pathways simultaneously, which trial sponsors have proposed may produce additive effects on food intake and body weight beyond either component alone.
Dosing ranges
| Tier | Dose | Frequency |
|---|---|---|
| Low | 0.25 mg | once weekly |
| Moderate | 1.7 mg | once weekly |
| High | 2.4 mg | once weekly |
Estimate your dose
Dose estimator
Educational estimate for CagriSema (Cagrilintide + Semaglutide), scaled to body size. Not medical advice.
Read before using
This tool produces a rough, educational estimate by scaling commonly-published research ranges to lean body mass. It is not a prescription, medical advice, or a substitute for a licensed clinician. Most peptides use fixed dosing, not weight-based dosing. Individual needs vary. You are solely responsible for how you use this information.
Mixing & syringe units
Target dose follows the estimate above. Change it there, or edit it directly below.
Reconstitution calculator
How much water to add and how many insulin-syringe units to draw for CagriSema (Cagrilintide + Semaglutide). Educational only.
Draw to this mark
34units
= 0.34 mL for a 1.7 mg dose
Concentration
5 mg/mL
Doses per vial
5
A U-100 syringe reads 100 units per mL. This is a reconstitution math helper only, not a prescription or dosing advice. Verify every calculation and consult a qualified healthcare provider.
Possible side effects
Stacking notes
As a fixed combination, it is not intended to be stacked with additional GLP-1 or amylin agents; doing so is not supported by evidence.
Common protocols
Common questions
What is CagriSema (Cagrilintide + Semaglutide) used for?
CagriSema is an investigational combination of cagrilintide, a long-acting amylin analog, and semaglutide, a GLP-1 receptor agonist, co-formulated as a single once-weekly injection. Phase 3 trial data have reported average weight reductions numerically greater than semaglutide alone in some analyses, positioning it among the more effective agents studied for weight management to date. It has not yet received regulatory approval. As with other late-stage investigational agents, published data are still limited relative to long-approved therapies. Reported benefits include associated with greater average weight loss than semaglutide monotherapy in some trial comparisons, combines two complementary satiety-signaling pathways, once-weekly injection schedule.
What is a typical CagriSema (Cagrilintide + Semaglutide) dose?
Reported ranges run 0.25-2.4 mg. A low protocol is 0.25 mg once weekly, and a high protocol is 2.4 mg once weekly. This is reference information, not a dosing recommendation.
What is the half life of CagriSema (Cagrilintide + Semaglutide)?
Approximately 7 days for each component, consistent with once-weekly dosing. That is what sets the dosing frequency, and it is why the timing guidance is weekly · same day, any time.
How is CagriSema (Cagrilintide + Semaglutide) administered?
Subcutaneous: into fat, under the skin. Co-formulated combination product; dosing figures reflect the semaglutide-equivalent titration scale used in published trials, alongside a matched cagrilintide component.
How long is a CagriSema (Cagrilintide + Semaglutide) cycle?
Continuous use with titration over several months in trial protocols on, followed by Not established outside of trial settings off. Titration pace mirrors semaglutide-based protocols to limit gastrointestinal side effects.
What are the side effects of CagriSema (Cagrilintide + Semaglutide)?
Reported side effects include nausea, vomiting, and diarrhea, especially during titration, decreased appetite, injection-site reactions, potential gallbladder-related events, long-term safety data remain limited. Evidence level for this compound is moderate evidence.
Partner offer · $20 off
When did you last
check your blood work?
Regular blood work catches changes early. At-home collection with free pickup, 50+ biomarkers, and results in 72 hours.
- 1Order your kitTakes two minutes online, $20 off with this link.
- 2Collect at homePainless draw with free home pickup, no lab visit.
- 3Results in 72 hours50+ biomarkers with clear optimal ranges.
Partner offer · opens rythm.health
Educational use only, not medical advice. This profile is provided for research and educational purposes. CagriSema (Cagrilintide + Semaglutide) may be a research compound or a prescription medication; nothing here is intended to diagnose, treat, cure, or prevent any disease. Dosing figures reflect commonly-published research ranges, not a prescription. Consult a qualified healthcare provider before making any health decision. Read the full disclaimer →